Maamoun Salam, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1598077760
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,763 of the $17,174 with a category attached, or 62.7%. 19 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 56.7% of the total. Reporting peaked in 2024 at $11,533 and has fallen 94.4% since, to $643 in 2025.
Across 95 payments — averaging $180.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$10K
- Lilly USA, LLC$4K
- Bayer$1K
- Novo Nordisk$422
- Dexcom, Inc.$401
- BETA Bionics, Inc.$336
- plus $2K from 13 others
Across 188 payments — averaging $959.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$101K
- Neurocrine Biosciences, Inc.$80K
What the payments were for
- Consulting fees$10,76363%
- Travel & lodging$2,35214%
- Food & beverage$4,06024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 15 | $9,746 |
| Lilly USA, LLC | 15 | $3,651 |
| Bayer | 11 | $1,019 |
| Novo Nordisk | 17 | $422 |
| Dexcom, Inc. | 8 | $401 |
| BETA Bionics, Inc. | 3 | $336 |
| Medtronic | 3 | $257 |
| Chiesi USA, Inc. | 3 | $212 |
| Amgen | 3 | $176 |
| Abbott | 8 | $158 |
| Sequel Med Tech, LLC | 1 | $149 |
| Sanofi-aventis U.S. LLC | 1 | $149 |
| Radius Health, Inc. | 1 | $122 |
| Senseonics, Incorporated | 1 | $118 |
| Tandem Diabetes Care, Inc. | 1 | $115 |
| Ascendis Pharma Endocrinology Inc | 1 | $83 |
| Lifescan, Inc. | 1 | $29 |
| AstraZeneca | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$1,999
- iLet Bionic Pancreas$980
- Kerendia$653
- MINIMED 780G$157
- TWIIST$149
- TZIELD$149
- DEXCOM G7 GSS (161)$143
- Wegovy$122
- Tymlos$122
- Eversense$118
- DEXCOM G6 TRANSMITTER$116
- t:slim X2 Insulin Pump with Control-IQ$115
- MYALEPT$108
How this compares
$17,174 in reported general payments places this provider in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 389 | $481,162 |
| JardianceEmpagliflozin | 202 | $231,280 |
| MounjaroTirzepatide | 128 | $154,498 |
| TrulicityDulaglutide | 122 | $140,443 |
| FarxigaDapagliflozin Propanediol | 96 | $88,784 |
| Humalog Kwikpen U-200Insulin Lispro | 33 | $70,327 |
| JanuviaSitagliptin Phosphate | 72 | $61,259 |
| Tresiba Flextouch U-100Insulin Degludec | 72 | $39,589 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 42 | $34,332 |
| VascepaIcosapent Ethyl | 66 | $28,271 |
| RybelsusSemaglutide | 16 | $27,685 |
| Humalog Kwikpen U-100Insulin Lispro | 75 | $22,478 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $21,086 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $20,750 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 163 | $18,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $422 | $516,026433 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $3,651 | $324,265321 claims |
| AstraZenecaFarxiga | $16 | $88,78496 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $149 | $10,59312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Janet McGillSaint Louis$212K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
- Julie SilversteinSaint Louis$49K
- Michael WhyteSaint Louis$40K
- Alexis McKeeSaint Louis$37K
- Sandeep DhindsaSaint Louis$36K
- Thomas NickolasSaint Louis$35K
- K ThampySaint Louis$35K
- Garry TobinSaint Louis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.